. 2017 Sep 29;22:64–68. doi: 10.1016/j.gore.2017.09.012

Table 1.

Summary of UTROSCT cases with metastasis, recurrence, or extrauterine spread of primary tumor.

Source	Age, y	Surgical management	Mitotic activity	Myometrial invasion	Serosal involvement	LVSI	Location of metastasis or extrauterine extension	Adjuvant therapy	Follow-up, mo	Treatment for recurrence and follow-up
Kantelip, 1985	86	TAH, BSO, epiploic mass resection	Scarce mitotic figures	…	+ (Cyst ruptured through serosa)	−	Left ovary and epiploica;	N/A	60	N/A
Kantelip, 1985	86	TAH, BSO, epiploic mass resection	Scarce mitotic figures	…	+ (Cyst ruptured through serosa)	−	LNs not evaluated	N/A	60	N/A
Umeda, 2014	38	1) Transvaginal myomectomy;	MIB-1, 3%	+	−	+	Left internal iliac lymph node	High-dose progesterone therapy	11	N/A
Umeda, 2014	38	2) TAH, BSO, PLND	MIB-1, 3%	+	−	+	Left internal iliac lymph node	High-dose progesterone therapy	11	N/A
Umeda, 2014	57	TAH, BSO, appendectomy	MIB-1, 1%	−	−	+	Epiploic appendix;	N/A	96	N/A
Umeda, 2014	57	TAH, BSO, appendectomy	MIB-1, 1%	−	−	+	LNs not evaluated	N/A	96	N/A
Macak, 2014	53	1) Hysteroscopic polypectomy	Ki-67, 5%	…	−	−	Right internal iliac LN	N/A	10	N/A
Macak, 2014	53	2) Hysterectomy, BSO, PPLND	Ki-67, 5%	…	−	−	Right internal iliac LN	N/A	10	N/A
Gomes, 2016	53	1) SCH;	…	+	Myometrial involvement adjacent to serosa	+	Extension to cervix, right parametrium, and right ovarian hilum; pelvic LN negative	4 cycles of modified BEP, EBRT, and brachytherapy	60	N/A
Gomes, 2016	53	2) BSO, OMX, PLND, and cervix resection	…	+	Myometrial involvement adjacent to serosa	+		4 cycles of modified BEP, EBRT, and brachytherapy	60	N/A
Biermann, 2007	68	Hysterectomy	Ki-67, < 5%	+	−	−	No metastasis of primary tumor;	N/A	48 (intestinal obstruction, 10 cm bowel tumor)	Surgical resection; no follow-up noted
Biermann, 2007	68	Hysterectomy	Ki-67, < 5%	+	−	−	LNs not evaluated	N/A	48 (intestinal obstruction, 10 cm bowel tumor)	Surgical resection; no follow-up noted
O'meara, 2009	35	TAH	Ki-67, 5%	…	+	…	No metastasis of primary tumor;	N/A	36 (recurrent galactorrhea, pelvic mass infiltrating the bladder, abdominal wall, and intestine)	Extensive tumor debulking followed by BEP; patient doing well after 12 months
O'meara, 2009	35	TAH	Ki-67, 5%	…	+	…	LNs not evaluated	N/A
Endo, 2015	39	Hysterectomy	…	+	…	−	No metastasis of primary tumor;	N/A	276 (14.0 × 10.2 cm solid tumor invading the left pelvic wall)	1) 3 months of letrozole and medroxyprogesterone acetate with no response;
										2) Arterial embolization of tumor;
										3) Cytoreductive surgery; patient doing well after 20 months
							LNs not evaluated
Present case	49	5 cycles of NACT followed by optimal cytoreductive surgery	Mitotic activity high	+	1 mm from serosa	+	Bilateral ovarian surfaces, omentum, Morrison's pouch nodule;	2 cycles of carboplatin and docetaxel		Death from disease 2017
Present case	49	5 cycles of NACT followed by optimal cytoreductive surgery	Mitotic activity high	+	1 mm from serosa	+	LNs not evaluated	2 cycles of carboplatin and docetaxel		Death from disease 2017

Abbreviations: UTROSCT, uterine tumors resembling ovarian sex cord tumor; N/A, not applicable; TAH, total abdominal hysterectomy; SCH, supracervical hysterectomy; BSO, bilateral salpingo-oophorectomy; PLND, pelvic lymph node dissection; OMX, omentectomy; LN, lymph nodes; PLND, pelvic lymph node dissection; BEP, bleomycin, etoposide, cisplatin; EBRT, external beam radiation therapy; LVSI, lymphovascular space invasion; NACT, neoadjuvant chemotherapy.

… Not mentioned in article.

+ Present/− absent.